Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W)...

Full description

Bibliographic Details
Main Authors: Lajos Kemény, Lovisa Berggren, Martin Dossenbach, Yves Dutronc, Carle Paul
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Journal of Dermatological Treatment
Subjects:
Online Access:http://dx.doi.org/10.1080/09546634.2018.1473551

Similar Items